#ASCO21: Coherus, Junshi hunt US approval for anti-PD-1 drug in nose and throat cancer with late-stage win
The anti-PD-1/L1 market has grown increasingly packed in recent years with a slate of late additions looking to carve out market share. A Chinese competitor from Junshi Biosciences and Coherus is laser focusing on a predominantly Southeast Asian patient population, and its results there could be strong enough to pave a path to approval in the US.
Coherus and Junshi’s toripalimab added to first-line chemotherapy in nasopharyngeal cancer hits its marks in progression-free survival over chemo alone, adding some heft to the Chinese-made molecule’s chances at the US market, according to late breaking data set to be presented at this weekend’s #ASCO21.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.